ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - promethazine hydrochloride 25 mg - promethazine hydrochloride tablets are useful for: perennial and seasonal allergic rhinitis. vasomotor rhinitis. allergic conjunctivitis due to inhalant allergens and foods. mild, uncomplicated allergic skin manifestations of urticaria and angioedema. amelioration of allergic reactions to blood or plasma. dermographism. anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. preoperative, postoperative, or obstetric sedation. prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. therapy adjunctive to meperidine or other analgesics for control of post-operative pain. sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. active and prophylactic treatment of motion sickness. antiemetic therapy in postoperative patients. promethazine hydrochloride tablets are contraindicated for use in pediatric patients less than two years of age. promethazine hydrochloride tablets are contraindicated in comatose states, and in individuals known to be hypersensitive or to have had an idiosyncratic reaction to promethazine or to other phenothiazines. antihistamines are contraindicated for use in the treatment of lower respiratory tract symptoms including asthma.

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - ursodiol (unii: 724l30y2qr) (ursodiol - unii:724l30y2qr) - ursodiol 300 mg - - actigall is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. safety of use of actigall beyond 24 months is not established. - actigall is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. - actigall will not dissolve calcified cholesterol stones, radiopaque stones, or radiolucent bile pigment  stones. hence, patients with such stones are not candidates for actigall therapy. - patients with compelling reasons for cholecystectomy including unremitting acute cholecystitis, cholangitis, biliary obstruction, gallstone pancreatitis, or biliary-gastrointestinal fistula are not candidates for actigall therapy. - allergy to bile acids.

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - lovastatin (unii: 9lhu78oqfd) (lovastatin - unii:9lhu78oqfd) - lovastatin 10 mg - therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-c and ldl-c to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. primary prevention of coronary heart disease in individuals without symptomatic cardiovascular disease, average to moderately elevated total-c and ldl-c, and below average hdl-c, lovastatin is indicated to reduce the risk of: -  myocardial infarction -  unstable angina -  coronary revascularization procedures (see clinical pharmacology, clinical studies.) coronary heart disease lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-c and ldl-c to target leve

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide   inhalation solution 0.02%   read complete instructions carefully before using. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir (figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of vi

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - triamterene (unii: ws821z52lq) (triamterene - unii:ws821z52lq), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - triamterene 37.5 mg - this fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked.   - triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. - triamterene and hydrochlorothiazide tablets are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). triamterene and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive drugs, such as beta-blockers. since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do no

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 25 mg in 5 ml - nitrofurantoin oral suspension is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of escherichia coli , enterococci, staphylococcus aureus , and certain susceptible strains of klebsiella and enterobacter species. nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. consequently, many patients who are treated with nitrofurantoin are predisposed to persistence or reappearance of bacteriuria. urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. if persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin, other therapeutic agents with broader tissue distribution should be selected. in considering the use of nitrofurantoin, lower eradication rates should be balanced against the increased potential for systemic tox

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - hydroxocobalamin acetate (unii: s535m27n3q) (hydroxocobalamin - unii:q40x8h422o) - hydroxocobalamin 1000 ug in 1 ml - - pernicious anemia, both uncomplicated and accompanied by nervous system involvement. pernicious anemia, both uncomplicated and accompanied by nervous system involvement. - dietary deficiency of vitamin b12 , occurring in strict vegetarians and in their breast-fed infants. (isolated vitamin b12 deficiency is very rare). dietary deficiency of vitamin b12 , occurring in strict vegetarians and in their breast-fed infants. (isolated vitamin b12 deficiency is very rare). - malabsorption of vitamin b12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin b12 absorption. these conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). folate deficiency in these patients is usually more severe than vitamin b12 deficiency. malabsorption of vitamin b12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin b12 absorption. these conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). folate deficiency in these patients is usually more severe than vitamin b12 deficiency. - inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). total gastrectomy always produces vitamin b12 deficiency. structural lesions leading to vitamin b12 deficiency include regional ileitis, ileal resections, malignancies, etc. inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). total gastrectomy always produces vitamin b12 deficiency. structural lesions leading to vitamin b12 deficiency include regional ileitis, ileal resections, malignancies, etc. - competition for vitamin b12 by intestinal parasites or bacteria. the fish tapeworm (diphyllobothrium latum) absorbs huge quantities of vitamin b12 and infested patients often have associated gastric atrophy. the blind-loop syndrome may produce deficiency of vitamin b12 or folate. competition for vitamin b12 by intestinal parasites or bacteria. the fish tapeworm (diphyllobothrium latum) absorbs huge quantities of vitamin b12 and infested patients often have associated gastric atrophy. the blind-loop syndrome may produce deficiency of vitamin b12 or folate. - inadequate utilization of vitamin b12 . this may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. inadequate utilization of vitamin b12 . this may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. - for the schilling test. for the schilling test.

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - clindamycin phosphate (unii: eh6d7113i8) (clindamycin - unii:3u02el437c) - clindamycin 10 mg in 1 ml - clindamycin phosphate topical solution, usp 1% is indicated in the treatment of acne vulgaris. in view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (see contraindications, warnings and adverse reactions ). clindamycin phosphate topical solution is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis. safety and effectiveness in pediatric patients under the age of 12 have not been established. clinical studies for clindamycin phosphate topical solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - diphenhydramine hydrochloride, usp 2% zinc acetate, usp 0.1% - topical analgesic skin protectant for the temporary relief of pain and itching associated with • minor burns   • sunburn   • minor cuts   • scrapes  • insect bites   • minor skin irritations • rashes due to poison ivy, oak and sumac • dries the oozing and weeping of poison: • ivy  • oak  • sumac • on large areas of the body   • with any other product containing diphenhydramine, even one taken by mouth • on chicken pox   • on measles • condition gets worse • symptoms persist for more than 7 days or clear up and occur again within a few days

ABD - İngilizce - NLM (National Library of Medicine)

actavis pharma, inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use ● because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see warnings and precautions ( 5.1 )] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be